Company Overview - Savara is a clinical-stage biotechnology company focused on developing inhaled biologics for rare respiratory diseases, with its lead product, molgramostim, in late-stage clinical trials [4] - The company aims to address significant unmet medical needs in the orphan drug segment of the healthcare industry [4] Financial Metrics - As of February 17, Savara's stock price was $5.73, with a market capitalization of $1.1 billion [3] - The company reported a net income of -$118.8 million for the trailing twelve months (TTM) [3] Investment Activity - VR Adviser, LLC increased its position in Savara by 1,059,332 shares during the fourth quarter, bringing its total holdings to 13,740,375 shares valued at $82.85 million [5][8] - Savara represents 4.1% of VR Adviser's total assets under management (AUM) of over $2 billion [5][8] Market Performance - Savara's shares gained 96.4% in the previous year, indicating strong market performance [6] - The company's stock is expected to trade based on regulatory approval news and potential revenue from its lead drug candidate [7] Product Development - Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase III development for autoimmune pulmonary alveolar proteinosis [9] - Revenue generation is anticipated to begin upon the commercialization of the product, targeting healthcare providers and institutions treating rare respiratory disorders [9]

Product Development and Clinical Trials - Savara's sole product candidate, MOLBREEVI, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and has enrolled 164 patients, exceeding the target of 160 patients[15]. - The IMPALA-2 trial reported positive top line results in June 2024, demonstrating significant improvement in hemoglobin adjusted gas exchange and clinical benefit, with a favorable risk-benefit profile for MOLBREEVI[20]. - Statistically significant improvements were observed in mean change from baseline in DLCO at Week 24 and Week 48, and in SGRQ Total Score at Week 24, indicating durability of effect[22]. - The Phase 3 IMPALA-2 trial enrolled 164 patients, exceeding the expected enrollment of 160, with a treatment discontinuation rate of only 3%[45][46]. - The primary endpoint of the IMPALA-2 trial showed a statistically significant treatment difference of 6.0 percentage points in hemoglobin adjusted percent predicted DLCO at Week 24 in favor of MOLBREEVI (p=0.0007)[47]. - At Week 48, the treatment difference in DLCO remained significant at 6.9 percentage points (p=0.0008), indicating durability of treatment effect[50]. - The SGRQ Total score showed a significant improvement of -6.59 points at Week 24 and -4.87 points at Week 48 in favor of MOLBREEVI compared to placebo[50]. - The ongoing IMPALA-2 trial is a global Phase 3 pivotal study comparing the efficacy and safety of MOLBREEVI 300 µg administered once daily by inhalation with a matching placebo[166]. - The IMPACT trial, evaluating MOLBREEVI in pediatric patients aged 6-<18 years, is currently ongoing as part of the Pediatric Investigational Plan accepted by the EU EMA and UK MHRA[54]. Regulatory Designations and Approvals - MOLBREEVI has received multiple designations from regulatory agencies, including Fast Track, Breakthrough Therapy, and Orphan Drug Designations from the FDA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA[17]. - The biologics license application (BLA) for MOLBREEVI was submitted to the FDA in March 2025, with a resubmission in December 2025 following a Refusal to File letter[15]. - MOLBREEVI received Orphan Drug Designation from the FDA in October 2012 and Fast Track Designation in May 2019, indicating its potential for expedited regulatory review[38][39]. - The FDA aims to review a BLA within ten months, or six months under Priority Review for serious conditions[101][105]. - The company completed the rolling BLA submission to the FDA in March 2025 and requested Priority Review[109]. - The FDA indicated that the data provided for the MOLBREEVI development program did not provide sufficient evidence of efficacy and safety for the treatment of autoimmune PAP[175]. - Conditional marketing authorizations in the EU can be granted for orphan medicinal products, valid for one year and renewable until comprehensive data is provided[120]. - Orphan Drug Designation in the U.S. must be requested before submitting a BLA, providing potential exclusivity for seven years upon first approval[127]. Manufacturing and Supply Chain - Savara has established a long-term supply agreement with PARI for the proprietary eFlow® nebulizer system, which is integral to the MOLBREEVI drug-device combination[15]. - The company plans to qualify a second source drug product manufacturer following the commercialization of MOLBREEVI to ensure a dual source supply chain[15]. - MOLBREEVI drug substance is manufactured by GEMA Biotech S.A. and Fujifilm, with ongoing validation activities for commercial manufacturing[63]. - MOLBREEVI drug product is produced by Patheon, with technology transfer completed in 2023 to a new filling line[64]. - The eFlow® Nebulizer System, used for administering MOLBREEVI, is CE certified and has a 510(k) clearance in the U.S.[66]. - The company relies on third-party contract manufacturers for the production of its product candidate, MOLBREEVI, and any disruptions in supply could adversely affect clinical trials and commercialization[210]. - The company faces potential challenges in scaling up production of its product candidate, which may be necessary for maximizing commercial value[213]. Financial Performance and Projections - For the year ended December 31, 2025, the company incurred a net loss of $118.8 million and net cash used in operating activities was $101.0 million[196]. - As of December 31, 2025, the company's cash, cash equivalents, and short-term investment securities totaled approximately $235.7 million, with working capital around $221.2 million[196]. - The company has an accumulated deficit of $608.1 million as of December 31, 2025, and expects to continue incurring substantial operating losses for the next several years[196]. - The company may require additional financing to support operations, and failure to obtain necessary capital could delay or terminate product development efforts[197]. - The Hercules Loan Agreement allows the company to borrow up to $105 million, with $30 million already borrowed, but includes restrictive covenants that could impact business operations[200]. - Adverse developments in the financial services industry could impact the company's liquidity and access to financing[207]. Market and Competitive Landscape - The estimated diagnosed prevalence of autoimmune PAP is six to seven cases per million people in the U.S., with potentially higher prevalence in other regions[27]. - Sargramostim (Leukine) has been approved in Japan for the treatment of autoimmune PAP based on a multicenter clinical trial, which may present a competitive threat to MOLBREEVI in that market[155]. - The pharmaceutical industry is highly competitive, with potential competitors having greater financial, technical, and human resources, which could impact the company's market position[154]. - Market acceptance of MOLBREEVI among the medical community and patients is uncertain, which could limit revenue generation[189]. Compliance and Legal Risks - The company must ensure compliance with cGMP regulations to avoid disruptions in production or distribution[111]. - The company is subject to the federal Anti-Kickback Statute, which prohibits remuneration in exchange for patient referrals, with potential legal scrutiny for non-compliance[133]. - The False Claims Act (FCA) imposes liability for knowingly presenting false claims, with significant penalties and multi-million to multi-billion dollar settlements being common[134]. - The company must comply with the Health Insurance Portability and Accountability Act (HIPAA) and its amendments, which impose strict requirements on the privacy and security of health information[135]. - The Affordable Care Act includes provisions that impose a nondeductible fee on manufacturers of branded drugs, increasing Medicaid rebate percentages to 23.1% for branded drugs[145]. - Non-compliance with healthcare laws can result in severe penalties, including exclusion from federal healthcare programs and reputational harm[141]. Employee and Organizational Structure - The company has approximately 70 employees and several third-party consultants, with no employees represented by a labor union[156]. - The company is committed to attracting and retaining talent through a competitive compensation program and a spot bonus program for notable achievements[157]. - The company emphasizes the importance of diversity and inclusion in its workforce and provides training on these topics to all employees[160]. - The health and safety of employees is a top priority, with measures in place to allow remote work[161]. Risks and Challenges - The company faces various risks related to the development and commercialization of its product candidate, including potential delays in clinical trials and regulatory approvals[169]. - The company has never obtained regulatory approvals for or commercialized a product candidate, which poses a significant risk to its business[165]. - The testing and approval process can take several years and may encounter delays or additional costs[102]. - The company may face significant delays in regulatory approval due to changes in regulations or policies, which could impact the development timeline[181]. - The FDA may impose restrictions on the approved uses of MOLBREEVI, limiting its commercial potential[182]. - The company may need to conduct additional clinical trials if initial results are negative or inconclusive, increasing development costs[178]. - The regulatory approval process in other countries may differ significantly from that in the U.S., posing additional risks[194]. - The company may reduce expenditures on the development of MOLBREEVI if market acceptance is deemed inadequate[191].

Core Insights - Savara Inc. reported significant advancements in the development of MOLBREEVI for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), including the submission of Marketing Authorization Applications (MAAs) to the EMA and MHRA, and a Biologics License Application (BLA) to the FDA with a PDUFA date set for August 22, 2026 [1][1][1] Financial Results - For Q4 2025, Savara's net loss was $32.2 million, or $(0.13) per share, compared to a net loss of $29.0 million, or $(0.13) per share in Q4 2024 [1][1][1] - Research and development expenses for Q4 2025 were $20.9 million, down from $23.3 million in Q4 2024, while general and administrative expenses increased to $12.5 million from $7.8 million [1][1][1] - For the fiscal year 2025, the net loss was $118.8 million, or $(0.53) per share, compared to a net loss of $95.9 million, or $(0.48) per share in 2024 [1][1][1] - Research and development expenses for the year increased by $3.4 million, or 4.3%, to $81.4 million, primarily due to costs associated with the MOLBREEVI program [1][1][1] - General and administrative expenses rose by $17.0 million, or 68.0%, to $42.1 million, driven by higher personnel costs and strategic workforce expansion [1][1][1] Cash Position - As of December 31, 2025, Savara had approximately $236 million in cash and short-term investments, with access to an additional $150 million in non-dilutive capital upon FDA approval of MOLBREEVI [1][1][1] Regulatory Milestones - MOLBREEVI has received multiple designations, including Fast Track, Breakthrough Therapy, and Orphan Drug Designation from the FDA and EMA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA [1][1][1] Business Strategy - The company is preparing for U.S. commercial planning, including the onboarding of a market development team expected to be completed in Q2 2026 [1][1][1]

Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding the potential health benefits and risks and projected development timeline of MOLBREEVI; the timing of regulatory submissions; the potential for ...

Summary of Savara's Conference Call Company Overview - **Company**: Savara - **Focus**: Orphan rare pulmonary respiratory diseases - **Lead Candidate**: MOLBREEVI (molgramostim) under FDA review with a PDUFA date of August 22, 2023 [5][17] Disease Context - **Condition**: Autoimmune Pulmonary Alveolar Proteinosis (PAP) - **Characteristics**: Rare autoimmune disease affecting individuals globally, with no specific demographic predilection [5][10] - **Symptoms**: Shortness of breath, cough, fatigue, leading to significant morbidity and debilitation [10][11] - **Current Treatment**: Limited options including supportive care and a complex procedure called whole lung lavage, which is not standardized and requires significant resources [11][12] Mechanism of Action - **MOLBREEVI**: A recombinant GM-CSF inhaled once daily, designed to overcome autoantibodies that inhibit GM-CSF from activating macrophages [13][14] Clinical Data - **IMPALA2 Trial**: The largest and longest study in autoimmune PAP, enrolling 164 subjects in a 48-week double-blind placebo-controlled trial [17][18] - **Results**: - Primary endpoint (DLco) met at 24 weeks and maintained through 48 weeks, showing statistical significance [18][19] - Secondary endpoints (SGRQ total, SGRQ activity, exercise tolerance) also showed significant improvement [19][20] - **Publication**: Data published in The New England Journal of Medicine [21] Commercial Strategy - **Prevalence Estimates**: Diagnosed prevalence in the U.S. estimated at 15-16 per million, with a total of approximately 5,500 prevalent patients identified [37][39] - **Target Audience**: Approximately 1,700 key accounts and 4,000-5,000 pulmonologists targeted for outreach [44][46] - **Testing Initiatives**: Offering a no-cost dried blood spot card antibody test to aid in diagnosis [50][51] Regulatory and Financial Position - **BLA Submission**: Recently accepted by the FDA with priority review granted; no Advisory Committee required [28] - **Cash Position**: $264 million on the balance sheet, with additional non-dilutive capital available upon FDA approval [58] - **Pricing Strategy**: Expected pricing range of $400,000-$500,000 per patient per year, with positive feedback from payers regarding budget impact [57] Launch Preparations - **Sales Force**: Approximately 27 representatives planned to target the market effectively [59] - **International Strategy**: Plans to file for MAA in Europe and the U.K., with intentions to maintain full control of the asset [55][56] Key Takeaways - Savara is positioned to address a significant unmet need in the treatment of autoimmune PAP with MOLBREEVI, supported by robust clinical data and a strategic commercial plan [5][17][57] - The company is actively preparing for a potential launch in August 2023, with a focus on patient identification and education within the pulmonology community [50][55]

Core Viewpoint - Savara Inc. has received a Day 74 Letter from the FDA indicating that an Advisory Committee meeting is not planned for the MOLBREEVI Biologics License Application (BLA), with the review process ongoing and a PDUFA target action date set for August 22, 2026 [1] Company Updates - The FDA's Day 74 Letter signifies that the review of the MOLBREEVI BLA is continuing without the need for an Advisory Committee meeting [1] - The Prescription Drug User Fee Act (PDUFA) target action date for the MOLBREEVI application is August 22, 2026, indicating a timeline for potential approval [1]

Summary of Savara's Conference Call Company Overview - **Company**: Savara - **Focus**: Clinical stage biopharmaceutical company specializing in rare respiratory diseases - **Product**: Developing MOLBREEVI, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for autoimmune pulmonary alveolar proteinosis (APAP) [1][3] Recent Progress - **FDA Submission**: BLA (Biologics License Application) accepted by the FDA with a priority review assigned, PDUFA date set for August 22nd [3][4] - **Clinical Trials**: Positive results from the global phase III study (IMPALA-2) for APAP, supporting confidence in the approval process [3][6] Unmet Need and Treatment Landscape - **Current Situation**: No approved therapies for APAP in the U.S. and Europe; existing treatment involves a mechanical procedure (whole lung lavage) that is not standardized and only available in select centers [8][10] - **MOLBREEVI's Advantage**: Addresses the underlying pathophysiology of APAP by activating macrophages, improving gas exchange and surfactant homeostasis [11] Market Potential - **Patient Population**: Estimated 5,500 diagnosed patients in the U.S., equating to approximately 16 patients per million, which is within the published range of 6-26 patients per million for this rare disease [14][15] - **Treatment Accessibility**: All identified patients could potentially benefit from MOLBREEVI upon approval, with physicians indicating willingness to prescribe it regardless of disease severity [15][19] Commercial Strategy - **Field Force**: Plans to establish a commercial field force of approximately 30 customer-facing personnel, focusing on the top 500 accounts that manage two-thirds of the patient population [20][21] - **Partnerships**: Selected PANTHERx Rare as the exclusive specialty pharmacy, leveraging their experience in rare diseases and existing relationships with pulmonary offices [22][23] Financial Position - **Cash Reserves**: As of the last report, Savara has $264 million in cash, with potential access to an additional $150 million in non-dilutive financing upon FDA approval [26][27] - **Funding Strategy**: Includes a royalty agreement and a debt facility to support operations and commercialization efforts [27] Additional Insights - **Launch Preparations**: Ongoing disease awareness campaigns and educational initiatives are being conducted to prepare for the commercialization of MOLBREEVI [24][25] - **Long-term Outlook**: The company is well-funded and positioned for a successful launch, with a strong focus on addressing the needs of APAP patients [27][28]

Core Viewpoint - Savara Inc. has announced that the FDA has filed for review the Biologics License Application (BLA) for MOLBREEVI, aimed at treating patients with autoimmune pulmonary alveolar proteinosis (PAP), marking a significant milestone for the company and the autoimmune PAP community [1] Group 1 - The FDA has granted Priority Review for the BLA, with a Prescription Drug User Fee Act (PDUFA) action date set for August 22, 2026 [1] - The filing of the BLA is seen as a step closer to potential approval for a new therapy in the treatment of autoimmune PAP [1]

Core Viewpoint - Savara Inc. has announced that the FDA has filed for review the Biologics License Application (BLA) for MOLBREEVI, aimed at treating patients with autoimmune pulmonary alveolar proteinosis (PAP), marking a significant milestone for both the company and the autoimmune PAP community [1] Group 1 - The FDA has granted Priority Review for the BLA, with a Prescription Drug User Fee Act (PDUFA) action date set for August 22, 2026 [1]

Summary of Savara's Conference Call Company Overview - **Company**: Savara - **Focus**: Single asset company specializing in orphan rare pulmonary diseases - **Key Asset**: MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis (APAP) [3][4] Core Points and Arguments - **Regulatory Progress**: - Resubmitted Biologics License Application (BLA) for MOLBREEVI in December, expecting FDA acceptance soon [3][4] - Anticipates priority review due to Breakthrough Therapy Designation, with PDUFA date projected for August [4] - Plans to file Marketing Authorization Applications (MAAs) in Europe and the UK by the end of Q1 [4] - **Manufacturing Changes**: - Shifted to Fujifilm as the primary drug substance manufacturer after a refusal to file due to manufacturing data issues [5][6] - Alignment achieved with FDA on analytical comparability protocol with Fujifilm [6][8] - **Clinical Data**: - Strong Phase 3 results published in the New England Journal, with DLCO as the primary endpoint showing statistical significance at 24 weeks [9][10] - Key secondary endpoints also demonstrated clinical benefit, including SGRQ and exercise tolerance tests [10][11] - **Market Potential**: - Identified approximately 5,500 diagnosed patients in the U.S., with a goal to confirm 1,000 patients by the end of 2025 [18][19] - Market is concentrated, with top 500 accounts representing about two-thirds of the market [19][20] - **Commercial Strategy**: - Partnering with PANTHERx, a specialty pharmacy, to facilitate product launch and patient access [21] - Ongoing disease awareness campaigns targeting both physicians and patients to increase diagnosis and treatment uptake [24][25] - **Pricing Strategy**: - Pricing corridor established between $400,000 and $500,000 per patient per year, with payers showing willingness to cover under typical prior authorization criteria [32] - **International Plans**: - Plans to commercialize in Europe and the UK independently, with a similar market opportunity as the U.S. [33] - Japan's market strategy remains under evaluation, with potential differences in approach compared to Europe and the UK [35] Additional Important Information - **Patient Awareness**: - Disease awareness campaigns have successfully identified newly diagnosed patients, indicating a potential for higher prevalence than previously estimated [25][27] - **Financial Position**: - Well-funded with $264 million on the balance sheet and potential for $75 million in royalties upon FDA approval [39] - Restructured debt facility allows for up to $150 million in non-dilutive capital upon FDA approval [39] - **Upcoming Catalysts**: - Anticipated updates regarding FDA decision by the end of January, with a focus on maintaining communication with stakeholders [38]